HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Stocks · News reference
8-K filing — Oruka Therapeutics, Inc. (ORKA)
Filed: 2026-08-24 AccNo: 0001213900-26-093021 Size: 300 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oruka Therapeutics Files Prospectus For Offering $1B Mixed Shelf
https://www.sec.gov/Archives/edgar/data/907654/000121390026092612/ea0301041-s3_oruka.htm
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.